Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Show more

40 Guest Street, Boston, MA, 02135, United States

Biotechnology

Healthcare

Market Cap

113.9M

52 Wk Range

$4.98 - $45.50

Previous Close

$27.01

Open

$27.42

Volume

57,406

Day Range

$26.86 - $27.60

Enterprise Value

100.5M

Cash

16.38M

Avg Qtr Burn

-10.94M

Insider Ownership

18.59%

Institutional Own.

14.96%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CUE-221 (Anti-IgE Antibody) Details Chronic Spontaneous Urticaria	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-102 Details Recurrent Glioblastoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-101 (IL-2) +/- pembrolizumab Details HPV+ head and neck squamous cell carcinoma (HNSCC)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-221 (Anti-IgE Antibody) Details Food Allergy	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-401 (Tolerogenic IL-2 Fusion) Details Autoimmune Diseases	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.